Острые лейкозы

НОВАЯ СТАТЬЯ

APL to FCR Tenodesis Suspensionplasty in Addition to Mini Tightrope Suspensionplasty and Trapeziectomy for Basal Joint Osteoarthritis: Clinical and Radiological Outcomes.

This study aims to compare the clinical and radiological outcomes of adding FCR-APL tenodesis to suture-button suspensionplasty following trapeziectomy in the treatment of Basal Joint Osteoarthritis (BJOA).This study is based on a prospectively collected cohort, comparing patients treated with trapeziectomy and suture-button suspensionplasty, with (n=14) or without (n=18) additional APL-FCR suspensionplasty, followed until one month postoperatively...

DOI: 10.1055/a-2571-4375
Hsieh J, Chang HM, Lo IN, Wu SL, Wang JP, Huang YC
Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V..., 2025-06-01

High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial.

Whether adding anthracycline to intermediate- or high-dose cytarabine as consolidation is beneficial remains unclear in acute myeloid leukemia (AML)...

DOI: 10.1038/s41375-025-02655-x
Zhang Y, Feng Z, Du J, Liu H, Yu S, Liang X, Zhao W, Zhang Q, Zhang X, Nie D, Sun Z, Du X, Xu X, Yu G, Shi P, Liu Q, Shao R, Qu H, Xiong W, Wang S, Jiang Y, Zhang H, Guo Z, Dai M, Jiang X, Xu D, Huang F, Fan Z, Xu N, Liu C, Wu M, Lin R, Jin H, Sun J,
Leukemia, 2025-05-31

Improved outcomes over time in patients aged ≥60 years undergoing allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in first complete remission: a large study by the EBMT acute leukemia working party.

Allogeneic hematopoietic cell transplantation remains an important curative treatment for patients with acute lymphoblastic leukemia (ALL)...

DOI: 10.1038/s41409-025-02630-1
Moukalled N, Ferhat AT, Bazarbachi A, Blaise D, Broers AEC, Castilla-Llorente C, Wagner-Drouet E, Halkes C, Schroeder T, Passweg J, Yakoub-Agha I, Dreger P, Kröger N, Fanin R, Gabellier L, Blau IW, Brissot E, Nagler A, Giebel S, Mohty M, Ciceri F
Bone marrow transplantation, 2025-05-30

Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia.

The influence of genetic ancestry on genomics in T-cell Acute Lymphoblastic Leukemia (T-ALL) has not been fully explored...

DOI: 10.1158/2643-3230.BCD-25-0049
Newman H, Lee SHR, Pölönen P, Shraim R, Li Y, Liu H, Aplenc R, Bandyopadhyay S, Chen C, Devidas M, Diorio C, Dunsmore K, Elghawy O, Elhachimi A, Fuller T, Gupta S, Hall J, Hughes AD, Hunger SP, Loh ML, Martinez Z, McCoy MF, Mullen CG, Pounds SB, Raet
Blood cancer discovery, 2025-05-31

Oncogenomic profiling in infant-toddler T-ALL identifies NKX2 family genes as drivers linked to favorable outcomes.

T-cell acute lymphoblastic leukemia (T-ALL) is a rare and aggressive hematological malignancy primarily affecting adolescents and young adults and is scarce in infants and toddlers under age 3...

DOI: 10.1002/hem3.70154
Delafoy M, Balducci E, Simonin M, Pinton A, Charbonnier G, Courtois L, Lhermitte L, Gillet C, Féroul M, Touzart A, Cieslak A, Smith C, Courgeon M, Wiber M, Mercher T, Latour S, Arnoux I, Saultier P, Rohrlich PS, Bodet D, Grardel N, Lubnau M, Pellier
HemaSphere, 2025-05-31

Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non-low-risk AML.

The standard induction treatment for acute myeloid leukemia (AML) has limited efficacy for patients with non-low-risk AML.

DOI: 10.1182/bloodadvances.2024014901
Marconi G, Piciocchi A, Audisio E, Papayannidis C, Cerrano M, Minotti C, Paoloni F, Guolo F, Bocchia M, Rondoni M, Lico A, Carrabba MG, Della Porta MG, Frigeni M, Giaccone L, Beltrami G, Cattaneo C, Di Chio MC, Serio B, Crea E, Freilone R, Capria S,
Blood advances, 2025-05-31

Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy.

У данной статьи нет абстракта.

DOI: 10.1182/bloodadvances.2024015712
Shaw R, Yoon JJ, Johnston H, Davidson MB, Siddon AJ, Shallis RM, Chen EC, Burkart M, Oh TS, Iyer SG, Madarang E, Muthiah C, Kassner J, Rampal RK, Guru Murthy GS, Bradley T, Abaza Y, Garcia JS, Gupta V, Pettit KM, Odenike O, Patel AA
Blood advances, 2025-05-31